Thrilled to attend this complement-fest. #C3G satellite meeting today promises novel insights and productive discussion (and my lightning C3G immunostaining presentation!) watch this #EMCHD2019 space complephiles!

Joshua Thurman reminds us that confound factors, esp non-specific loss of GFR, must be quantified before applying potential complement biomarkers to clinical practice (fig from Jalal et al, JAHA 2018) #emchd2019

Outstanding key note C1q story from Marina Botto #emchd2019 Paradigm-shifting data made accessible with explanations like, of course C1q has functions independent of Ig because it phylogenetically predates Immunoglobulin science.sciencemag.org/content/360/63…

📖 For this weekend don't miss our KIReports #FridaySelection: Glomerular Complement Factor H–Related Protein 5 Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment. 👉🏼 doi.org/10.1016/j.ekir… Nick Medjeral-Thomas Imperial Medicine #GraphicalAbstract #ThisIsISN

Thanks to all collaborators on the Mintac trial. Results will empower patients with minimal change disease to make informed choices about their treatment. Nick Medjeral-Thomas Marie Condon Bhrigu Raj Sood Jonathan Barratt Neil Turner Christopher Lawrence Prof Liz B 🇬🇧🇮🇱🇺🇦🇵🇸 Jeremy Levy Charles Pusey

#KidneyWk #MinimalChange groundbreaking study showing it is possible to avoid steroids in patients with minimal change

Grilling them? Ha, nah, more like praising them. Important work from Megan Griffith and Nick Medjeral-Thomas providing an efficacious alternative to high dose steroids for minimal change podocytopathy. @LGlomcon #KidneyWk

Glomerular complement deposition, in particular FHR5. Next 😉

MinTac Trial: Tacrolimus monotherapy can be an effective alternative treatment for patients wishing to avoid steroid therapy for minimal change disease ca. 2020 from @CJASN Nick Medjeral-Thomas Megan Griffith Jonathan Barratt Neil Turner Charles Pusey #Nephpearls 👉🏼 cjasn.asnjournals.org/content/early/…

#NephJC. Nick Medjeral-Thomas. MinTac author. No other COI

Patients themselves often ask if there's an alternative an alternative to steroids. #NephJC

What to do with the relapses. Rechallenge with Tac? #nephjc

Thank you for hosting Nephrology Journal Club #NephJC

Pleased to see our paper available preprint. Huge collaborative effort from clinicians, scientists, dialysis nurses and patients Imperial College London Imperial Department of Immunology & Inflammation Imperial NHS 💙 Michelle Willicombe Maria Stephen McAdoo Nick Medjeral-Thomas

Proud to be part of this huge effort from scientists and clinicians to detail longitudinal proteomic profiles of end-stage kidney disease patients with #COVID19 #medRxiv Imperial Department of Immunology & Inflammation Imperial NHS 💙 Candice Clarke Jack Gisby medrxiv viewer disq.us/t/3splu24

This describes our experience managing #haemodialysis patients with #COVIDー19 Imperial NHS 💙 community dialysis unit incl risk factors for deterioration and (zero) staff infections kireports.org/article/S2468-…

Incredible work by Jack Gisby , Jimmy Peters and many others Imperial Department of Immunology & Inflammation Imperial College London Imperial NHS 💙 renal and transplant centre Candice Clarke Michelle Willicombe elifesciences.org/articles/64827